Organic year-on-year revenue growth for the quarter was 6.2% and adjusted EBIT margin was 16.6%, or 180 basis points better than the prior year period. Management raised full-year guidance for organic revenue growth to 4% from 3%-4%. Shares closed 7% higher than the previous day's close.
Now that it has been spun off, GEHC is able to focus on R&D and operational efficiency without competing internally with GE’s other business lines.
GEHC does not have a long record of operating as a stand-alone company.
|
Metric
|
GEHC
|
SHL
|
PHIA
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.63 | 19.81 | 13.33 |
Price/Book Value | 2.98 | 2.51 | 2.05 |
Price/Sales | 1.61 | 2.07 | 1.33 |
Price/Cash Flow | 13.37 | 15.03 | 9.27 |
|
Metric
|
GEHC
|
SHL
|
PHIA
|
|---|---|---|---|
Quick Ratio | 0.89 | 0.74 | 0.73 |
Current Ratio | 1.30 | 1.16 | 1.26 |
Interest Coverage | 7.25 | 7.88 | 5.51 |
|
Metric
|
GEHC
|
SHL
|
PHIA
|
|---|---|---|---|
Return on Assets (Normalized) | 6.01% | 5.00% | 6.09% |
Return on Equity (Normalized) | 20.83% | 12.25% | 14.83% |
Return on Invested Capital (Normalized) | 11.87% | 12.99% | 9.41% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|!<w<tW | LOCK|d$s@Z | $184B | |||
| Medtronic PLC
MDT
| LOCK|&CW<<> | LOCK|?K#H | $123B | |||
| Stryker Corp
SYK
| LOCK|@^YV@K@t | LOCK|c>B | $111B | |||
| Boston Scientific Corp
BSX
| LOCK|d>r%Y?t | LOCK|lc^f | $61B | |||
| Edwards Lifesciences Corp
EW
| LOCK|DX^#nQz | LOCK|!>YR | $53B | |||
| DexCom Inc
DXCM
| LOCK|?ph#!!Q | LOCK|#>ZF | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|L?P | LOCK|@S | $26B | |||
| Steris PLC
STE
| LOCK|tWd@@!T | LOCK|DDXPL | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|!wcq<X!D | LOCK|Bw | $18B |
United States